乳腺癌他莫昔芬耐药机制的研究进展

doi:10.11904/j.issn.1002-3070.2017.02.013

Abstract

Abstract: Tamoxifen(TAM)is an important therapeutic strategy for the treatment of estrogen receptor(ER)-positive breast cancer.However,tamoxifen resistance is a major cause of endocrine therapy failure.The potential mechanism of TAM resistance is multifactorial and most of them are still unknown.This review presents recent advances in the mechanism of TAM resistance in breast cancer,providing valuable information and ideas for elucidating the mechanism of tamoxifen resistance and overcoming drug resistance.

Key words: Tamoxifen, Breast cancer, Estrogen receptors, Resistance

CLC Number:

R737.9

YU Fei,HU Jing,CHEN Xuesong. Research progress of tamoxifen resistance mechanism in breast cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(2): 160-164.

References

1 Ojo D,Wei F,Liu Y,et al.Factors promoting tamoxifen resistance in breast cancer via stimulating breast cancer stem cell expansion[J].Curr Med Chem,2015,22(19):2360-2374.
2 Nass N,Kalinski T.Tamoxifen resistance:From cell culture experiments towards novel biomarkers[J].Pathol Res Pract,2015,211(3):189-197.
3 Yin L,Pan X,Zhang XT,et al.Downregulation of ER-α36 expression sensitizes HER2 overexpressing breast cancer cells to tamoxifen[J].American Journal Cancer Research,2015,5(2):530-544.
4 Droog M,Beelen K,Linn S,et al.Tamoxifen resistance:From bench to bedside[J].Eur J Pharmacol,2013,717(1-3):47-57.
5 Early Breast Cancer Trialists′ Collaborative Group,Davies C,Godwin J,et al.Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen:Patient-level meta-analysis of randomised trials[J].Lancet,2011,378(9793):771-784.
6 Pietras RJ,Marquez-Garban DC.Membrane-associated estrogen receptor signaling pathways in human cancers[J].Clin Cancer Res,2007,13(16):4672-4676.
7 Yang X,Phillips DL,Ferguson AT,et al.Synergistic activation of functional estrogen receptor(ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells[J].Cancer Res,2001,61(19):7025-7029.
8 Fuqua SA,Wiltschke C,Zhang QX,et al.A hypersensitive estrogen receptor-α mutation in premalignant breast lesions[J].Cancer Res,2000,60(15):4026-4029.
9 Toy W,Shen Y,Won H,et al.ESR1 ligand-binding domain mutations in hormone-resistant breast cancer[J].Nat Genet,2013,45(12):1439-1445.
10 Merenbakh-Lamin K,Ben-Baruch N,Yeheskel A,et al.D538G mutation in estrogen receptor-α:A novel mechanism for acquired endocrine resistance in breast cancer[J].Cancer Res,2013,73(23):6856-6864.
11 Jeselsohn R,Yelensky R,Buchwalter G,et al.Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer[J].Clin Cancer Res,2014,20(7):1757-1767.
12 Niu J,Andres G,Kramer K,et al.Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients[J].Onco Targets Ther,2015,11(8):3323-3328.
13 Robinson DR,Wu YM,Vats P,et al.Activating ESR1 mutations in hormone-resistant metastatic breast cancer[J].Nat Genet,2013,45(12):1446-1451.
14 Yu T,Liu M,Luo H,et al.GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells[J].Steroid Biochem Mol Biol,2014,9(143):392-403.
15 Mo Z,Liu M,Yang F,et al.GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer[J].Breast Cancer Res,2013,15(6):R114.
16 Ignatov A,Ignatov T,Weissenborn C,et al.G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer[J].Breast Cancer Res Treat,2011,128(2):457-466.
17 Pupo M,Pisano A,Abonante S,et al.GPER activates Notch signaling in breast cancer cells and cancer-associated fibroblasts(CAFs)[J].Int J Biochem Cell Biol,2014,1(46):56-67.
18 Rakha EA,El-Sayed ME,Green AR,et al.Prognostic markers in triple-negative breast cancer[J].Cancer,2007,109(1):25-32.
19 Ciupek A,Rechoum Y,Gu G,et al.Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer[J].Breast Cancer Res Treat,2015,154(2):225-237.
20 Cochrane DR,Bernales S,Jacobsen BM,et al.Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide[J].Breast Cancer Res,2014,16(1):7.
21 Ramaswamy B,Lu Y,Teng KY.et al.Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant brest cancer aberrantly activated by PI3K/AKT pathway[J].Cancer Res,2012,72:5048-5059.
22 Matevossian A,Resh MD.Hedgehog acyltransferase as a target in estrogen receptor positive,HER2 amplified,and tamoxifen resistant breast cancer cells[J].Mol Cancer 2015,4(14):72-87.
23 Villegas VE,Rondon-Lagos M,Annaratone L,et al.Tamoxifen treatment of breast cancer cells:Impact on Hedgehog/GLI1 signaling[J].Int J Mol Sci,2016,17(3):308-320.
24 O′Toole SA,Machalek DA,Shearer RF,et al.Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer[J].Cancer Res,2011,71(11):4002-4014.
25 Noman AS,Uddin M,Rahman MZ,et al.Overexpression of Sonic Hedgehog in the triple negative breast cancer:Clinicopathological characteristics of high burden breast cancer patients from bangladesh[J].Sci Rep,2016,1(6):18830-18841.
26 Van Schooneveld E,Wildiers H,Vergote I,et al.Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patientmanagement[J].Breast Cancer Res,2015,2(17):21-36.
27 Garofalo M,Quintavalle C,Romano G,et al.miR221/222 in cancer:Their role in tumor progression and response to therapy[J].Curr Mol Med,2012,12(1):27-33.
28 Lu Y,Roy S,Nuovo G,et al.Anti-microRNA-222(anti-miR-222)and-181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal[J].Biol Chem,2011,286(49):42292-42302.
29 Sachdeva M,Mo YY.MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1[J].Cancer Res,2010,70(1):378-387.
30 Shi W,Gerster K,Alajez NM,et al.MicroRNA-301 mediates proliferation and invasion in human breast cancer[J].Cancer Res,2011,71(8):2926-2937.
31 Ward A,Shukla K,Balwierz A,et al.MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer[J].Pathol,2014,233(4):368-379.
32 Hoppe R,Achinger-Kawecka J,Winter S,et al.Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment[J].Eur J Cancer,2013,49(17):3598-3608.
33 Zhang W,Xu J,Shi Y,et al.The novel role of miRNAs for tamoxifen resistance in human breast cancer[J].Cell Mol Life Sci,2015,72(13):2575-2584.
34 Li CH,Chen Y.Targeting long non-coding RNAs in cancers:Progress and prospects[J].Int J Biochem Cell Biol,2013,45(8):1895-1910.
35 Hayes EL,Lewis-Wambi JS.Mechanisms of endocrine resistance in breast cancer:An overview of the proposed roles of noncoding RNA[J].Breast Cancer Res,2015,5(17):40.
36 Su X,Malouf GG,Chen Y,et al.Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes[J].Oncotarget,2014,5(20):9864-9876.
37 Xue X,Yang YA,Zhang A,et al.LncRNA HOTAIR enhanceser signaling and confers tamoxifen resistance in breast cancer[J].Oncogene,2016,35(21),2746-2755.
38 Xing Z,Lin A,Li C,et al.LncRNA directs cooperative epigenetic regulation downstream of chemokine signals[J].Cell,2014,159(5):1110-1125.

[1]	WANG Xiaoya,XIAO Bin,LIAO Yang,TANG Rongzhi,SUN Zhaohui,LI Linhai. Expression of CXCR family proteins in different subtypes of breast cancer and their clinical prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 206-210.
[2]	LI Shuo,ZHANG Nannan,LI Liangliang,LONG Zhiping,YIN Huihui,ZHAO Yashuang,WANG Fan. Relationship between PDE4C gene methylation in peripheral blood leukocytes,interaction of environmental factors and pathogenesis of breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 233-238.
[3]	CHEN Yanbo, KONG Dejia, ZHANG Jinfeng, MA Zhigang. Correlation between CYP2D6 gene polymorphism and tamoxifen metabolism in breast cancer patients [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 110-114.
[4]	SUN Jianghong, HAO Mingzhu, JIANG Dan, GUO Fei, LI Xiaomei. FFDM differential diagnosis of mastitis,benign hyperplasia and breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 139-141.
[5]	MA Zhijie, WANG Fan, ZHAO Yashuang. Analysis of life quality and influencing factors in breast cancer patients with chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 149-154.
[6]	MA Zhingying, SHANG Naijian, CAI Miaotian, SHEN Yang, JIANG Zhiyun. Correlation between HER-2 receptor of progesterone and estrogen receptor-positive breast cancer and mammography imaging & clinicopathological features [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 47-51.
[7]	LI Wanzhen, YIN Jun, LI Ping, LIN Xiaohui, ZHANG Guoqian, ZHANG Shuxu. The expression and role of miR-17 in radioresistant cells of non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 391-397.
[8]	HE Xu, YE shangmian, DONG dandan, LI Ke. The expression of HLA-G in breast cancer and its significance [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 410-414.
[9]	LIN Rongjie, YIN Hang, ZHOU Yunfeng. Effect of ON123300 on ER+ human breast cancer MCF-7 cells and its mechanism [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 193-197.
[10]	LI Lin, LI Zhigao. The relationship between metformin and different molecular subtypes of breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 267-270.
[11]	ZHENG Wei, XU Shouping, PANG Da. Expression,prognosis and function of long chain non-coding RNA-Linc00152 in breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 7-13.
[12]	YIN Yulian, ZHANG Weihong, ZHOU Yue, YE Meina, CHEN Hongfeng. Correlation between single nucleotide polymorphisms of ERα gene and bone loss associated with aromatase inhibitors in postmenopausal women with breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 14-18.
[13]	LI Yujiao, SHANG Naijian. Research progress of imaging evaluation of neoadjuvant chemotherapy in breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 63-67.
[14]	CHEN Zhuo, KONG Yiran. Effect of silencing UHRF1 on proliferation and metastasis of breast cancer cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 512-518.
[15]	LI Hongyang, SUN Liang, JIANG Xing, YUAN Guangjun, LIU Yan. Dauricine enhances the sensitivity of 5-fluorouracil in human breast cancer MCF-7 cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 385-389.

Research progress of tamoxifen resistance mechanism in breast cancer

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments